Anti-fibrotic effects of Astragaloside IV in systemic sclerosis

Area of Science:

• Pharmacology
• Fibrosis Research
• Autoimmune Diseases

Background:

• Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by widespread fibrosis.
• Fibroblast activation and excessive extracellular matrix deposition, particularly collagen and fibronectin, are hallmarks of SSc pathogenesis.
• Current treatments for SSc have limited efficacy in reversing established fibrosis.

Purpose of the Study:

• To investigate the anti-fibrotic potential of Astragaloside IV (AST) in systemic sclerosis.
• To elucidate the molecular mechanisms underlying AST's effects on fibroblast activation and extracellular matrix production.

Main Methods:

• Fibroblast cultures from SSc patients and normal individuals were treated with AST.
• Collagen and fibronectin expression were quantified using Western blot, RT-qPCR, and immunofluorescence.
• An in vivo SSc mouse model induced by bleomycin was used to assess AST's therapeutic effects.
• The TGF-β signaling pathway, including Smad3 and Fli-1, was analyzed.

Main Results:

• Astragaloside IV significantly reduced collagen and fibronectin expression in SSc fibroblasts in a dose- and time-dependent manner.
• In vivo studies demonstrated that AST decreased collagen formation and restored skin structure in SSc model mice.
• Mechanistically, AST was found to downregulate Smad3/Fli-1 signaling and inhibit p-SMAD3 nuclear translocation, key components of the TGF-β pathway.

Conclusions:

• Astragaloside IV exhibits significant anti-fibrotic effects in systemic sclerosis.
• The mechanism involves the inhibition of the TGF-β-Smads3 signaling axis.
• Astragaloside IV represents a potential therapeutic agent for managing fibrosis in SSc.